Carboplatin

A regimen of neoadjuvant nab-paclitaxel with carboplatin may be an effective anthracycline-free treatment with an acceptable pathological complete response rate among triple negative breast cancer patients with BCRA1/2 mutations, according to research presented at ASCO 2021.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.

First-line treatment with carboplatin plus pemetrexed followed by maintenance pemetrexed appeared noninferior to docetaxel monotherapy in extending OS among older patients with advanced nonsquamous non-small cell lung cancer, according to results of a randomized phase 3 trial published in JAMA Oncology.

De-escalation of treatment after two cycles of chemotherapy and a negative PET scan appeared safe and feasible among a cohort of men with low-volume metastatic seminoma, according to results of a phase 2 trial presented at Genitourinary Cancers Symposium.

The FDA approved atezolizumab plus nab-paclitaxel and carboplatin for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, according to a manufacturer-issued press release.

The addition of pemetrexed and carboplatin chemotherapy to gefitinib significantly extended PFS and OS for patients with advanced non-small cell lung cancer and EGFR-sensitizing mutations, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.

Last month, I mentioned my favorite new oxymoron — “Environmental Protection Agency” — and am concerned you might have missed it if you were on vacation ... so I raise the topic again.

BARCELONA — The addition of durvalumab to platinum-etoposide chemotherapy significantly extended OS among patients with extensive-stage small cell lung cancer, according to results of the CASPIAN study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Chemoradiotherapy significantly improved OS and failure-free survival compared with pelvic radiotherapy alone among women with high-risk endometrial cancer, according to results from the PORTEC-3 randomized phase 3 trial published in The Lancet Oncology.